

IAP2 Rec'd PCT/PTO 29 SEP 2006

1

DESCRIPTION

PROCESS FOR PRODUCING CHIRAL HYDROXYALDEHYDE COMPOUNDS

Technical Field

5 The present invention relates to a process for producing a hydroxyaldehyde compound, comprising conducting aldol condensation of a substituted or unsubstituted aliphatic aldehyde compound having 2 to 6 carbon atoms with a single molecule of acetaldehyde, or by further conducting aldol
10 condensation with a second acetaldehyde molecule to produce the hydroxyaldehyde compound having the number of carbon atoms increased by two or four compared to that of the starting aliphatic aldehyde compound.

15 Background Art

D-2-deoxyribose-5-phosphate aldolase (EC4.1.2.4) (hereinafter, referred to as "DERA" for short) is a generic name for an enzyme which catalyzes aldol condensation which synthesizes D-2-deoxyribose-5-phosphate from glyceraldehyde-3-phosphate and acetaldehyde as substrates, and a reverse reaction thereof (retro-aldol reaction). Reactivity of *Escherichia coli* (*E. coli*)-derived DERA was analyzed in detail, and reported to have a relatively wide spectrum of substrate-specificity, thus catalyze aldol condensation of various aldehydes to produce chiral hydroxyaldehydes (See Non-Patent Document 1).

As shown in the reaction scheme of Fig. 1, it is reported that in the aldol condensation of various aldehydes with

acetaldehyde, a compound having the number of carbon atoms increased by four compared to that of the starting aldehyde is obtained by subjecting a hydroxyaldehyde, which is resulted from aldol condensation of a single molecule of aldehyde and a single molecule of acetaldehyde, to further aldol condensation with another single molecule of acetaldehyde. It has been reported that this compound resulting from aldol condensation with two molecules of acetaldehyde is produced as the main reaction product because the compound takes a stable lactol structure (See Non-Patent Document 2).

However, the conventionally known activity of DERA to various aldehydes as described above is reported to be extremely low, and to be less than 1/100 of the activity with respect to glyceraldehyde-3-phosphate and acetaldehyde, which are the original substrates (See Non-Patent Document 3). It is also reported that aldehydes are strong inhibitors to enzymes, and DERA is also inhibited by aldehydes (See Non-Patent Document 4). Accordingly, aldol condensation of these aldehydes requires a large amount of the enzyme. For example, Patent Document 1 described above discloses the synthesis of a 2,4,6-trideoxyhexose derivative via a 4-substituted-3-hydroxybutylaldehyde intermediate, wherein an increased amount of D-2-deoxyribose-5-phosphate aldolase to the degree of 125 U/mmol to 150 U/mmol was added, relative to the total number of moles of the substrates, namely, acetaldehyde and substituted acetaldehyde. Similarly, it is believed that even the reaction of condensation one acetaldehyde molecule requires the addition

of an increased amount of the enzyme to the degree of 80 U/mmol to 100 U/mmol. Furthermore, for the purpose of alleviating inhibition, multiple addition of aldehydes and DERA is also being investigated (See Patent Document 2).

5 The aldol condensation reaction by DERA has another problem in controlling the number of acetaldehyde molecules to be condensed. Although the attempts of changing the concentration ratio of two aldehydes subjected to the aldol condensation or changing the amount of enzyme have been made, it has been
10 difficult to control the number of acetaldehyde molecule, only except for the case of aldol condensation of several aldehydes having hydroxyl groups on the α -position or β -position, with acetaldehyde (See Non-Patent Document 5, Non-Patent Document 6 and Patent Document 3). Due to these problems, it has been
15 difficult to practicalize the aldol condensation by DERA.

From the viewpoint of highly stable DERA, a thermally stable DERA which is derived from a hyperthermophilic bacterium, *Aeropyrum pernix*, has been reported (See Patent Document 4). This enzyme is reported to have high thermal stability and high
20 stability against polar organic solvents such as methanol, ethanol and the like (See Non-Patent Document 8). Additionally, DERA derived from thermophilic bacteria such as *Thermotoga maritima*, *Thermus thermophilus* and the like have been reported, but nothing is reported concerning the stability against
25 aldehydes, activity on aldol condensation or the like of these thermophilic bacterium-derived DERA (See Non-Patent Document 9).

In general, a thermophilic bacterium-derived enzyme exhibits high activity in a high temperature region near the original growth temperature, and has significantly low activity in the normal temperature region. In the case of the aldol
5 condensation in which a highly reactive compound such as aldehyde is used as the substrate, a reaction in a high temperature region is predicted to be accompanied by various side reactions. Thus, it is necessary to perform the aldol reaction under low temperature conditions, and therefore, it is generally
10 inconceivable to use a thermophilic bacterium-derived DERA for the reaction. Furthermore, it was difficult to deduce that the enzyme would have high stability against aldehydes, merely from the fact that the enzyme has high thermal stability, since aldehydes have a property of being reactive to the lysine
15 residue or the like that are present in proteins.

[Patent Document 1] US Patent No. 5,795,749

[Patent Document 2] WO 03/006656

[Patent Document 3] WO 03/077868

[Patent Document 4] JP-A No. 2003-250553

20 [Non-Patent Document 1] J. Am. Chem. Soc., Vol. 112, pp. 2013-2014 (1990)

[Non-Patent Document 2] J. Am. Chem. Soc., Vol. 116, pp. 8422-8423 (1994)

[Non-Patent Document 3] J. Am. Chem. Soc., Vol. 114, pp. 741-748 (1992)
25

[Non-Patent Document 4] PNAS, Vol. 101, pp. 5788-5793 (2004)

[Non-Patent Document 5] J. Am. Chem. Soc., Vol. 117, pp.
3333-3339 (1995)

[Non-Patent Document 6] Angeu. Chem. Int. Ed., Vol. 39, pp.
1352-1374 (2000)

5 [Non-Patent Document 7] J. Am. Chem. Soc., Vol. 114, pp.
741-748 (1992)

[Non-Patent Document 8] J. Biol. Chem., Vol. 278, pp.
10799-10806 (2003)

[Non-Patent Document 9] J. Mol. Biol., Vol. 343, pp. 1019-
10 1034 (2004)

Disclosure of the Invention

It is an object of the present invention to provide an industrial process for producing hydroxyaldehydes efficiently, by solving the problems of conventional DERA, such as low stability against aldehydes, low catalytic activity for aldol condensation, and the difficulty of controlling the number of acetaldehyde molecules to be condensed.

The inventors have assiduously searched for a DERA having high stability against aldehydes and having high catalytic activity for aldol condensation. As a result, they found that DERA derived from hyperthermophilic bacteria, *Thermotoga maritima* and *Pyrobaculum aerophilum*, have remarkably high stability against aldehydes. Furthermore, they also found that although their activities at 25°C on natural substrates, namely, glyceraldehyde-3-phosphate and acetaldehyde, are significantly low compared with the conventional *E. coli*-derived enzyme, their

activities for aldol condensation reaction on non-natural substrates, such as aldehydes and acetaldehyde, are much higher than the activity of *E. coli*-derived DERA that has been reported previously. Moreover, they found that for DERA derived from the
5 hyperthermophilic bacterium, *Pyrobaculum aerophilum*, it is not likely that the β -hydroxyaldehyde resulting from aldol condensation of a single molecule of aldehyde with a single molecule of acetaldehyde undergoes further aldol condensation reaction with another single molecule of acetaldehyde, and a β -
10 hydroxyaldehyde having the number of carbon atoms increased by two is preferentially obtained. Thus, the invention has been completed.

For *Thermotoga maritima* and *Pyrobaculum aerophilum*, their genome information has been already disclosed (Nature, Vol. 399,
15 pp. 323-329 (1999); Pro. Natl. Acad. Sci. U.S.A., Vol. 99, pp. 984-989 (2002)), and based on this information, it has been presumed that there exists a DNA sequence which is believed to encode DERAs of both strains, from the viewpoint of its homology with *E. coli*-derived DERA. However, no detailed analysis is
20 conducted on these hyperthermophilic bacteria-derived DERAs, and it was also impossible to assume, prior to the present invention, that these DERAs have such effect. Thus, the invention is to demonstrate and disclose, for the first time, the effect of hyperthermophilic bacteria-derived DERAs on their applicability
25 to various aldol condensation reactions which has been unknown.

Thus, the invention relates to:

[1] A process for producing a hydroxyaldehyde compound, comprising conducting aldol condensation of a substituted or unsubstituted aliphatic aldehyde compound having 2 to 6 carbon atoms with a single molecule of acetaldehyde to produce a hydroxyaldehyde compound having the number of carbon atoms increased by two, using D-2-deoxyribose-5-phosphate aldolase having a property of retaining 50 % or greater of activity after treating at 25°C for 30 minutes in an aqueous medium containing 100 mM of chloroacetaldehyde and

[2] A process for producing a hydroxyaldehyde compound, comprising conducting aldol condensation of a substituted or unsubstituted aliphatic aldehyde compound having 2 to 6 carbon atoms with two molecules of acetaldehyde to produce a hydroxyaldehyde compound having the number of carbon atoms increased by four, using D-2-deoxyribose-5-phosphate aldolase (or cells containing the enzyme or a lysate thereof) having a property of retaining 50 % or greater of activity after treating at 25 C for 30 minutes in an aqueous medium containing 100 mM of chloroacetaldehyde.

According to the present invention, the productivity per reactor can be enhanced by using a small amount of DERA having high stability against aldehydes and high catalytic activity for aldol condensation. Further, it is possible to obtain a desired hydroxyaldehyde compound with high yield, by properly using a DERA which has high activity for aldol condensation of a single molecule of acetaldehyde, and a DERA which has high activity for aldol condensation of two molecules of acetaldehyde.

Brief Description of the Drawings

Fig. 1 is a schematic diagram illustrating sequential aldol reactions catalyzed by DERA.

5

Best Mode for Carrying Out the Invention

The residual activity of DERA after the treatment at 25°C for 30 minutes in an aqueous medium containing 100 mM chloroacetaldehyde is defined as the ratio of the total amount of 4-chloro-3-hydroxybutylaldehyde and 6-chloro-2,4,6-trideoxyhexose which are produced in a reaction started by the addition of 100 mM acetaldehyde at the final concentration and performed at 25°C for 2 hrs following the treatment of DERA at 25°C for 30 minutes in an aqueous solution containing 100 mM chloroacetaldehyde and 100 mM of buffer component at the appropriate pH value for the DERA being used in the present invention to the total amount of 4-chloro-3-hydroxybutylaldehyde and 6-chloro-2,4,6-trideoxyhexose in the control reaction which lacks the step of heat treatment of DERA. Moreover, in the present specification, the evaluation of the residual activity after a treatment at 25°C for 30 minutes in an aqueous medium containing 100 mM of chloroacetaldehyde, is simply referred to as "evaluation of chloroacetaldehyde resistance", and the value of the residual activity after a treatment at 25°C for 30 minutes in an aqueous medium containing 100 mM of chloroacetaldehyde may be abbreviated to "chloroacetaldehyde resistance value".

For the activity of DERA used in the present invention, the amount of enzyme which decomposes 1 μ mol of D-2-deoxyribose-5-phosphate to D-glyceraldehyde-3-phosphate and acetaldehyde in 1 minute at 25°C is defined as 1 U. The D-glyceraldehyde-3-phosphate produced by decomposition of D-2-deoxyribose-5-phosphate is quantified by the amount of decrease in NADH (reduced nicotinamide adenine dinucleotide), which results from conversion of D-glyceraldehyde-3-phosphate to dihydroxyacetone phosphate by triose phosphate isomerase and the subsequent reaction of dihydroxyacetone phosphate with glycerol-3-phosphate dehydrogenase.

The DERA used for the present invention is not limited, provided that it has a residual activity of 50% or greater after a treatment at 25°C for 30 minutes in an aqueous medium containing 100 mM of chloroacetaldehyde. Suitable example of such DERAs includes a DERA having an amino acid sequence of SEQ ID NO: 1-2 or a DERA having an amino acid sequence of SEQ ID NO: 24.

The DERA having an amino acid sequence of SEQ ID NO: 1-2 is obtained from, for example, *Thermotoga maritima* (JCM No. 10099) which is available from Japan Collection of Microorganisms (JCM). The amino acid sequence of SEQ ID NO: 1-2 may be a sequence having mutation introduced to the amino acid sequence of SEQ ID NO: 1-2 such that one to several amino acids are deleted or substituted by other amino acid residues, or other amino acid residues are inserted, as far as effects shown in the present invention are maintained.

The DERA having an amino acid sequence of SEQ ID NO: 2-4 is obtained from, for example, *Pyrobaculum aerophilum* (JCM No. 9630) which is available from JCM. The amino acid sequence of SEQ ID NO: 2-4 may be a sequence having mutation introduced to the amino acid sequence of SEQ ID NO: 2-4 such that one to several amino acids are deleted or substituted by other amino acid residues, or other amino acid residues are inserted, as far as effects shown in the present invention are maintained.

Recent progress in molecular biology and genetic engineering has made it possible, and also easier, to construct a genetically modified bacterium from arbitrary host by transforming the plasmid to which the above-mentioned gene of DERA and a regulatory region necessary for expression thereof was inserted. Considering such level of technology, a gene recombinant bacterium having the gene of DERA transfected into an arbitrary host is also included in the microorganism expressing DERA of the present invention. The regulatory region necessary for the gene expression as described herein refers to a promoter sequence (including an operator sequence regulating transcription), a ribosome-binding sequence (an SD sequence), a transcription termination sequence or the like. Examples of the promoter sequence include trp promoter of tryptophan operon derived from *E. coli*, lac promoter of lactose operon, PL promoter or PR promoter derived from lambda-phage, a gluconate synthase promoter (gnt) derived from *Bacillus subtilis*, an alkaline protease promoter (apr), a neutral protease promoter (npr), an α -amylase promoter (amy), and the like. Sequences

specifically designed and modified, such as tac promoter, may also be used. Examples of the ribosome-binding sequence include such sequences derived from *E. coli* or *B. subtilis*, but are not particularly limited, provided that such a sequence functions in a desired host such as *E. coli* or *B. subtilis*. For example, a consensus sequence in which a sequence of 4 or more consecutive bases is complementary to the 3'-terminal region of 16S ribosomal RNA, may be prepared in DNA synthesis and used for the purpose. The transcription termination sequence is not essentially needed, but the ones independent of the ρ factor, such as a lipoprotein terminator, a trp operon terminator and the like can be used. These regulatory regions on the recombinant plasmid are preferably arranged in the order of the promoter sequence, the ribosome-binding sequence, the gene encoding DERA, and the transcription termination sequence, from the 5'-terminus. Specific examples of the plasmid described herein that can be used as vector include pBR322, pUC18, Bluescript II SK (+), pKK223-3, pSC101, pET15b (available from Novagen, Inc.) and the like, which have a region capable of self-replication in *E. coli*, and pUB110, pTZ4, pC194, p11, ϕ 1, ϕ 105 and the like, which have a region capable of autonomic replication in *B. subtilis*. In addition, examples of the plasmid that is capable of autonomic replication in two or more species of host and can be used as vector include pHV14, TRp7, YEp7 and pBS7. The arbitrary host as described herein is exemplified by *Escherichia coli* such as *E. coli* BL21 [DE3] strain (available from Novagen, Inc.) as a representative

example, as described in the following Examples, but is not limited to *E. coli* in particular. Examples of the arbitrary host also include other microbial strains, such as bacteria belonging to Genus *Bacillus* such as *Bacillus subtilis*, yeasts
5 and Actinomycetes.

The techniques of gene recombination such as transformation can be performed according to the methods described in *Molecular Cloning, A Laboratory Manual*, 2nd Edition, Coldspring Harbor Laboratory Press (1989), and the like. The transformed
10 recombinant cells can be cultured under appropriate conditions, and DERA can be prepared from the culture product through known purification methods.


A hydroxyaldehyde compound having the number of carbon atoms increased by two compared to that of aliphatic aldehyde
15 compound can be prepared by conducting an aldol condensation reaction of the substituted or unsubstituted aliphatic aldehyde compound having 2 to 6 carbon atoms with a single molecule of acetaldehyde, in an aqueous medium containing 100 mM of chloroacetaldehyde, in the presence of D-2-deoxyribose-5-
20 phosphate aldolase having a property of retaining the residual activity of 50% or greater after a treatment at 25°C for 30 minutes. This aldol condensation reaction is usually conducted in an aqueous solution. During the reaction, an appropriate buffering component may be added for the purpose of maintaining
25 the optimal pH, or pH may be adjusted appropriately with acid or alkali. Furthermore, the reaction may be also conducted in the presence of an organic solvent which is miscible with water, or

an organic solvent which is immiscible with water, to an extent of not inhibiting the reaction.





For the substituted or unsubstituted aliphatic aldehyde compound having 2 to 6 carbon atoms, the substituted aliphatic aldehyde compound having 2 to 6 carbon atoms is a compound in which a hydrogen atom bonded to an arbitrary position of the unsubstituted aliphatic aldehyde compound having 2 to 6 carbon atoms (except for the hydrogen atom of an aldehyde group) is substituted by a substituent. Such substituent is not particularly limited as long as it does not adversely affect the aldol condensation reaction, and may be exemplified by a halogen atom, an azido group, a carboxyl group, an alkoxy group, an alkanoic acid group, and the like.



The substituted or unsubstituted aliphatic aldehyde compound having 2 to 6 carbon atoms may be exemplified by a compound represented by General Formula (1), General Formula (2), or General Formula (3). When these aliphatic aldehyde compounds are respectively subjected to aldol condensation with a single molecule of acetaldehyde, the compounds represented by General Formula (4), General Formula (5) and General Formula (6), which respectively correspond to the above aliphatic aldehyde compounds, are synthesized. Further, when the compound represented by General Formula (1) is subjected to aldol condensation with two molecules of acetaldehyde, a 3-5-hydroxyaldehyde compound represented by General Formula (7) is synthesized. Here, R_1 in General Formulae (1) to (7) is selected from a hydrogen atom, a hydroxyl group, a halogen atom, an azido

group, a carboxyl group or an alkoxy group having 1 to 4 carbon atoms. R_2 is selected from a hydrogen atom, a hydroxyl group or a methyl group. R_3 is selected from a hydrogen atom or a hydroxyl group.



5





The compound represented by General Formula (2) may be exemplified by acetaldehyde, chloroacetaldehyde, glycolaldehyde, propionaldehyde, butylaldehyde, isobutylaldehyde, 3,4-dihydroxybutylaldehyde, malonate semialdehyde, succinate semialdehyde, adipate semialdehyde, or the like. Chloroacetaldehyde in particular significantly exhibits the effect of the invention, and thus is used suitably. When chloroacetaldehyde is subjected to aldol condensation with a single molecule of acetaldehyde, 4-chloro-3-hydroxybutylaldehyde having the number of carbon atoms increased by two compared to that of the chloroacetaldehyde is synthesized, and when the 4-chloro-3-hydroxybutylaldehyde is sequentially subjected to aldol condensation with a second acetaldehyde molecule, 6-chloro-2,4,6-trideoxyhexose having the number of carbon atoms increased by four compared to that of the chloroacetaldehyde is synthesized. The compound represented by General Formula (3) may be typically exemplified by D-glyceraldehyde, isobutylaldehyde, or the like. The compound represented by

General Formula (4) may be exemplified by D-erythrose or 3,4-dihydroxybutylaldehyde.

The molar amount of acetaldehyde to be used with respect to the compound represented by General Formula (1), General Formula
5 (2) or General Formula (3) is suitably set to be in the range of 0.5 molar equivalents to 3.0 molar equivalents. For example, when chloroacetaldehyde is subjected to aldol condensation with a single molecule of acetaldehyde to synthesize 4-chloro-3-hydroxybutylaldehyde, the molar amount of acetaldehyde to be
10 used with respect to chloroacetaldehyde is typically set in a range of 0.5 molar equivalents to 1 molar equivalent. More preferably, when DERA having low activity of catalyzing aldol condensation with two molecules of acetaldehyde, such as *Pyrobaculum aerophilum* derived DERA is used, the molar amount of
15 acetaldehyde to be used with respect to chloroacetaldehyde can be set to be in the range of 0.5 molar equivalents to 3 molar equivalents, so as to synthesize 4-chloro-3-hydroxybutylaldehyde with good yield.

Further, when chloroacetaldehyde is subjected to aldol
20 condensation with two molecules of acetaldehyde to synthesize 6-chloro-2,4,6-trideoxyhexose, the molar amount of acetaldehyde to be used with respect to chloroacetaldehyde is typically set in a range of 2 molar equivalents to 3 molar equivalents. The use of DERA having high activity of catalyzing aldol condensation with
25 two molecules of acetaldehyde, such as *Thermotoga maritima*-derived DERA, is more desirable for the synthesis of 6-chloro-2,4,6-trideoxyhexose with good yield.

The amount of DERA to be used in the aforementioned reaction is defined within the following ranges. When a single molecule of acetaldehyde is subjected to aldol condensation to synthesize 3-hydroxyaldehyde, DERA can be used to react at a
5 ratio of 0.1 U/mmol to 80 U/mmol, relative to the total number of moles of the aldehyde compound represented by General Formula (1), General Formula (2) or General Formula (3), and acetaldehyde.

When two molecules of acetaldehyde are subjected to aldol
10 condensation to synthesize 3,5-dihydroxyaldehyde, DERA can be used to react at a ratio of 0.1 U/mmol to 120 U/mmol, relative to the total number of moles of the aldehyde compound represented by General Formula (1) and acetaldehyde.

For the present reaction described above, the pH range and
15 the reaction temperature may be suitably selected to provide optimal conditions by taking account of the yield of the desired product, and the like. For example, the pH range of the reaction solution is preferably pH 4 to 12, and more preferably pH 5 to 9. In preparing a buffer solution of a pH value in such
20 range, any pH buffering agent having sufficient buffering effect can be used. The reaction temperature can be selected from a range of 0°C to 100°C, but is preferably in the range of 0°C to 40°C, and more preferably in the range of 0°C to 25°C.

The time needed for the reaction may be favorably set to
25 provide the highest yield of the desired product. The desired product can be separated and recovered from the reaction

solution by known purification methods such as extraction, azeotropic distillation, crystallization and the like.

Hereinafter, the present invention will be described in more detail by way of Examples, but the invention is not

5 intended to be limited by these Examples.

EXAMPLE 1

Preparation of DERA derived from *Thermotoga maritima*

[1] Preparation of *Thermotoga maritima* chromosomal DNA

10 JCM237 medium [prepared as follows: a composition comprising 5.0 g of soluble starch, 0.5 g of KH_2PO_4 , 15.0 ml of mineral containing solution (containing 1.5 g of nitrilotriacetic acid, 3.0 g of $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$, 0.5 g of $\text{MnSO}_4 \cdot x\text{H}_2\text{O}$, 1.0 g of NaCl, 0.1 g of $\text{FeSO}_4 \cdot 7\text{H}_2\text{O}$, 0.1 g of $\text{CoSO}_4 \cdot 7\text{H}_2\text{O}$, 0.1 g of
15 $\text{ZnSO}_4 \cdot 7\text{H}_2\text{O}$, 0.01 g of $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$, 0.01 g of $\text{AlK}(\text{SO}_4)_2$, 0.01 g of H_3BO_3 , and 0.01 g of $\text{Na}_2\text{MoO}_4 \cdot 2\text{H}_2\text{O}$ per 1 L of distilled water; Preparation is done by dissolving nitrilotriacetic acid, followed by the adjustment of the pH value to 6.5 with KOH, the addition of the remaining minerals, and the adjustment of the
20 final pH value to 7.0), 2.0 mg of $\text{NiCl}_2 \cdot \text{H}_2\text{O}$, 20.0 g of NaCl, 0.5 g of Bacto yeast extract (available from Difco Laboratories, Inc.), 1.0 mg of resazurin, 0.5 g of $\text{Na}_2\text{S} \cdot 9\text{H}_2\text{O}$, 250 ml of artificial seawater (a composition prepared by dissolving 27.7 g of NaCl, 7.0 g of $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$, 5.5 g of $\text{MgCl}_2 \cdot 6\text{H}_2\text{O}$, 0.65 g of KCl, 0.1 g of NaBr, 30.0 mg of H_3BO_3 , 15.0 mg of $\text{SrCl}_2 \cdot 6\text{H}_2\text{O}$, 10.0 mg of
25 citric acid, 0.05 mg of KI, and 2.25 g of $\text{CaCl}_2 \cdot \text{H}_2\text{O}$ per 1 L of distilled water), and 750 ml of distilled water is prepared by

mixing all the components except $\text{Na}_2\text{S}\cdot 9\text{H}_2\text{O}$, and adjusting pH to 6.5 with H_2SO_4 . The composition is sterilized by filtration in a nitrogen atmosphere. The composition is used as a 5% solution to neutralize $\text{Na}_2\text{S}\cdot 9\text{H}_2\text{O}$, and is sterilized under high pressure

5 (121°C, 20 minutes) in a nitrogen atmosphere. Before inoculation, sterilized $\text{Na}_2\text{S}\cdot 9\text{H}_2\text{O}$ is added, and pH is adjusted to 6.5, if necessary] was used for culturing *Thermotoga maritima*. The preserved strain (JCM No. 10099) was incubated under stirring with a magnetic stirrer at 80°C for 24 to 96 hours,

10 while maintaining an anaerobic condition by nitrogen purging after deaeration, to prepare 2 L of the culture solution. After completion of the incubation, the bacteria in the resulting culture solution were harvested by centrifugation (5000 g, 10 minutes), and were washed with 3% NaCl. In 8 ml of TE buffer

15 solution (10 mM Tris-HCl (pH 7.5), 1 mM EDTA), 2g of the bacteria as wet bacterial weight was suspended. This bacterial suspension was mixed with 2 ml of a 10 mg/ml lysozyme solution and 100 μl of a 10 mg/ml RNase solution, and the mixture was incubated at 37°C for 30 minutes. Then, 50 μl of a 20 mg/ml

20 Proteinase K solution was added to the mixture, and after 10 minutes, 1 ml of a 30 mg/ml sodium N-lauroylsarcosine solution was added to the mixture. The resulting mixture was further incubated for 45 minutes. An equivalent volume of CI

(chloroform:isoamyl alcohol = 24:1) was added to the resulting

25 solution, with mild blending, and the mixture was centrifuged (7000 g, 15 minutes) to separate the aqueous layer. The same operation was repeated once more, and then a PCI treatment

(water-equilibrated phenol:CI = 1:1) was repeated twice in the same manner as in the CI treatment. The CI treatment was further carried out twice, then a 0.1-fold amount of 3 M sodium acetate was added to the aqueous layer with stirring, and an equivalent volume of isopropanol was added with gentle stirring. Precipitated DNA was wound up on a disposable tube, washed with 70% ethanol, dried, and dissolved in 500 µl of TE buffer solution, so as to obtain the *Thermotoga maritima* chromosomal DNA.

[2] Cloning of *Thermotoga maritima* DERA gene, and preparation of *E. coli* strain expressing DERA

A DNA fragment containing *Thermotoga maritima*-derived DERA gene of SEQ ID NO: 1 was obtained by PCR using oligonucleotides having the sequences of SEQ ID NO: 3-5 and SEQ ID NO: 4-6 as primers, and by using *Thermotoga maritima* chromosomal DNA as template. The obtained DNA fragment was treated with restriction enzymes NdeI and BamHI, and was ligated to a commercial expression vector pET15b (available from Novagen, Inc.) which had been treated similarly with NdeI and BamHI, to obtain a plasmid expressing *Thermotoga maritima*-derived DERA, pET15b-TM1559. This expression plasmid was used to transform *E. coli* BL21 [DE3] strain (available from Novagen, Inc.), so as to obtain *E. coli* BL21 [DE3]/pET15b-TM1559 expressing *Thermotoga maritima*-derived DERA.

[3] Purification of *Thermotoga maritima*-derived DERA from recombinant *E. coli*

The recombinant *E. coli* strain BL21 [DE3]/pET15b-TM1559 was inoculated to 100 ml of SB medium (12 g of tryptone, 24 g of yeast extract, 5 ml of glycerol, 12.5 g of K_2HPO_4 , and 3.8 g of KH_2PO_4 in 1 L) containing 50 μ g/ml of ampicillin, and was

5 cultured at 37°C until OD_{660} reached 0.6. Then, IPTG (isopropyl- β -thiogalactopyranoside) was added to a final concentration of 1 mM, and the culture was further continued for 3 hours. After completion of the culture, the bacteria were harvested by centrifugation (5000 g, 10 minutes), washed with a 0.85% NaCl

10 solution, and were suspended in a 10 mM Tris-HCl buffer solution (pH 7.5) with an amount of 9 times of the wet bacterial weight. The bacterial cells were disrupted by sonication and then centrifuged, and the supernatant was used as the crude enzyme solution. The crude enzyme solution was heated at 80°C for 10

15 minutes, and the denatured insoluble proteins were removed by centrifugation. A metal affinity column coordinated with nickel (HiTrap affinity column (available from Pharmacia Biotech, Inc.)) was equilibrated with a 10 mM Tris-HCl (pH 7.5) buffer solution containing 0.5 M NaCl and 10 mM imidazole, and then the

20 crude enzyme solution from which the insoluble proteins resulting from the heat treatment were removed, was applied thereon, and the active fractions were collected by eluting the protein with solution containing 0.1 M, 0.2 M, 0.3 M, 0.4 M, and 0.5 M of imidazole. The purity of *Thermotoga maritima*-derived

25 DERA thus obtained was analyzed by SDS-PAGE to confirm homogeneity. The amount of the protein was quantified by using

a Bio-Rad Protein Assay kit (available from Bio-Rad Laboratories, Inc.).

EXAMPLE 2

5 Preparation of DERA derived from *Pyrobaculum aerophilum*
JCM215 medium [prepared as follows: 125 ml of a marine
culture medium/synthetic seawater mixture (a solution prepared
by dissolving 47.15 g of NaCl, 18.10 g of $\text{MgCl}_2 \cdot 6\text{H}_2\text{O}$, 7.0 g of
 $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$, 3.13 g of $\text{CaCl}_2 \cdot 2\text{H}_2\text{O}$, 3.24 g of Na_2SO_4 , 0.1 g of Na_2CO_3 ,
10 0.1 g of NaBr, 80.0 mg of KBr, 72.0 mg of $\text{SrCl}_2 \cdot 6\text{H}_2\text{O}$, 52.0 mg of
 H_3BO_3 , 8.1 mg of Na_2HPO_4 , 2.4 mg of NaF, 0.4 mg of sodium silicate,
and 0.05 mg of KI in 1 L of distilled water), 10.0 ml of mineral
containing solution (a mineral solution comprising 1.5 g of
nitrilotriacetic acid, 3.0 g of $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$, 0.5 g of $\text{MnSO}_4 \cdot x\text{H}_2\text{O}$,
15 1.0 g of NaCl, 0.1 g of $\text{FeSO}_4 \cdot 7\text{H}_2\text{O}$, 0.1 g of $\text{CoSO}_4 \cdot 7\text{H}_2\text{O}$, 0.1 g of
 $\text{ZnSO}_4 \cdot 7\text{H}_2\text{O}$, 0.01 g of $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$, 0.01 g of $\text{AlK}(\text{SO}_4)_2$, 0.01 g H_3BO_3 ,
and 0.01 g of $\text{Na}_2\text{MoO}_4 \cdot 2\text{H}_2\text{O}$ per 1 L of distilled water;
Preparation is done by dissolving nitrilotriacetic acid,
followed by the adjustment of the pH value to 6.5 with KOH, the
20 addition of the remaining minerals, and the adjustment of the
final pH value to 7.0), 2.0 mg of $\text{Fe}(\text{NH}_4)_2 \cdot 6\text{H}_2\text{O}$, 0.25 g of NH_4Cl ,
2.0 mg of $(\text{NH}_4)_2\text{Ni}(\text{SO}_4)_2 \cdot 6\text{H}_2\text{O}$, 0.1 mg of Na_2SeO_4 , 0.1 mg of
 $\text{NaWO}_4 \cdot 2\text{H}_2\text{O}$, 2.2 g of NaHCO_3 , 0.07 g of KH_2PO_4 , 0.5 g of Bacto
yeast extract (available from Difco Laboratories, Inc.), 1.0 g
25 of $\text{NaS}_2\text{O}_3 \cdot 5\text{H}_2\text{O}$, and 865.0 ml of distilled water were mixed and
dissolved, and the pH value of the solution was adjusted to 7.0
with 1 N H_2SO_4 , and then the resulting solution was sterilized by

filtration. The medium was placed in an incubator under an atmosphere of gas containing nitrogen, carbon dioxide and oxygen at a mixing ratio of 80:20:1] was used for culturing *Pyrobaculum aerophilum*. After inoculation, the culture was performed at 95°C with a pressure of 200 kPa. The *Pyrobaculum aerophilum* chromosomal DNA was prepared from the preserved strain (JCM No. 9630) in the same manner as in Example 1. A DNA fragment containing *Pyrobaculum aerophilum* -derived DERA gene of SEQ ID NO: 2-3 was obtained by PCR using oligonucleotides having the sequences of SEQ ID NO: 5-7 and SEQ ID NO: 6-8 as primers, and by using the *Pyrobaculum aerophilum* chromosomal DNA as template. The initiation codon GTG of the *Pyrobaculum aerophilum*-derived DERA gene was changed to ATG for the purpose of expression in *E. coli*. The sequence of SEQ ID NO: 2-3 indicates the DNA sequence after the change.

The obtained DNA fragment was treated with restriction enzymes NdeI and BamHI, and was ligated to a commercial expression vector pET15b which had been treated similarly with NdeI and BamHI, to obtain a plasmid expressing *Pyrobaculum aerophilum*-derived DERA, pET15b-PAE1231. This expression plasmid was used to transform *E. coli* BL21 [DE3] strain, so as to obtain *E. coli* strain BL21 [DE3]/pET15b-PAE1231 expressing *Pyrobaculum aerophilum*-derived DERA.

Purification of the *Pyrobaculum aerophilum*-derived DERA from the recombinant *E. coli* strain BL21 [DE3]/pET15b-PAE1231 was performed according to the same method described in [3] of Example 1.

REFERENCE EXAMPLE 1

Purification of *E. coli*-derived DERA

A DNA fragment containing *E. coli*-derived DERA gene was
5 obtained from cultured bacterial cells of *E. coli* W3110 (ATCC No.
27325) which is available from the American Type Culture
Collection (ATCC), by PCR using oligonucleotides having the
sequences of SEQ ID NO: 7-9 and SEQ ID NO: 8-10 as primers, and
by using the *E. coli* chromosomal DNA prepared in the same manner
10 as in Example 1, as template. This DNA fragment containing *E.*
coli-derived DERA gene was treated with restriction enzymes NdeI
and BamHI, and was ligated to a commercial expression vector
pET11b (available from Novagen, Inc.) which had been treated
similarly with NdeI and BamHI, to obtain a plasmid expressing *E.*
15 *coli*-derived DERA, pET11b-DERA. This expression plasmid was
used to transform *E. coli* BL21 [DE3] strain to obtain *E. coli*
strain BL21 [DE3]/pET11b-DERA expressing *E. coli*-derived DERA.
A crude enzyme solution was prepared from the recombinant *E.*
coli according to the method described in Example 1, which was
20 fractionated by the ammonium sulfate precipitation method (50 to
70% of the saturation concentration), and then was dialyzed
against a 50 mM Tris-HCl (pH 7.5) buffer solution. This
dialyzed crude enzyme solution was applied to Phenyl 5PW
hydrophobic chromatography (manufactured by Tosoh Corp.) and the
25 proteins were eluted with 50 mM Tris-HCl (pH 7.5) buffer with
linear concentration gradient of ammonium sulfate from 1 to 0 M.
The collected active fractions were analyzed by SDS-PAGE to

confirm homogeneous purification of *E. coli*-derived DERA. The amount of proteins was quantified by using a Bio-Rad Protein Assay kit.

5 EXAMPLE 3

Comparison of activity for D-2-deoxyribose-5-phosphate decomposition

The activities of *Thermotoga maritima*-derived DERA obtained in Example 1, *Pyrobaculum aerophilum*-derived DERA obtained in
10 Example 2, and *E. coli*-derived DERA obtained in Reference Example 1, for D-2-deoxyribose-5-phosphate decomposition at 25°C were measured. The measurement was performed by converting D-glyceraldehyde-3-phosphate, which was resulted from the decomposition of D-2-deoxyribose-5-phosphate by DERA, to
15 dihydroxyacetone phosphate with triose phosphate isomerase, and the subsequent reaction of dihydroxyacetone phosphate with glycerol-3-phosphate dehydrogenase. The quantification was performed by measuring the consumed NADH by glycerol-3-phosphate dehydrogenase.

20 The components excluding D-2-deoxyribose-5-phosphate, triose phosphate isomerase, glycerol-3-phosphate dehydrogenase, and NADH from 1 ml of the activity measurement solution (50 mM of triethanolamine-HCl (pH 7.5), 0.5 mM of D-2-deoxyribose-5-phosphate, 3.9 U of triose phosphate isomerase (available from
25 Sigma-Aldrich Co.), 11 U of glycerol-3-phosphate dehydrogenase (available from Sigma-Aldrich Co.), 0.12 mM of NADH, and the active fraction subject to measurement), were incubated at a

constant temperature of 25°C for 3 minutes, and then the remaining components were added thereto to start the measurement. While keeping the temperature at 25°C, the decrease in the absorbance at 340 nm was measured for 1 minute using an appropriate spectrophotometer. One unit (U) of DERA activity was defined as the amount of enzyme required to reduce 1 μ mol of NADH per 1 minute at 25°C. The molar absorption coefficient of NADH at 340 nm was taken as 6.22 $\text{mM}^{-1}\text{cm}^{-1}$. The enzyme activities (U) thus measured of *Thermotoga maritima*-derived DERA, *Pyrobaculum aerophilum*-derived DERA and *E. coli*-derived DERA at 25°C per 1 mg of DERA are presented in Table 1.

[Table 1]

Enzyme	Enzyme Activity
<i>Thermotoga maritima</i> -derived DERA	0.58 U
<i>Pyrobaculum aerophilum</i> -derived DERA	0.10 U
<i>E. coli</i> -derived DERA	61.1 U

EXAMPLE 4

Evaluation of resistance to chloroacetaldehyde

In a 100 mM citric acid-sodium citrate buffer solution (pH 6.5) containing 100 mM of chloroacetaldehyde, 250 μ g of *Thermotoga maritima*-derived DERA was added, and the mixture was incubated at 25°C for 30 minutes. After the incubation, acetaldehyde was added to the solution at a concentration of 100 mM, and an aldol condensation reaction was performed at 25°C for 2 hours. For the control, 250 μ g of *Thermotoga maritima*-derived DERA was added to a 100 mM citric acid-sodium citrate buffer solution (pH 6.5) containing 100 mM of chloroacetaldehyde, followed by the addition of acetaldehyde to the solution at a

concentration of 100 mM, and then aldol condensation reaction was performed at 25°C for 2 hours. The reaction was terminated by filtering the reaction solution through an ULTRAFREE-MC filter (manufactured by Millipore Corp.) to remove the proteins, and the amounts of 4-chloro-3-hydroxybutylaldehyde and 6-chloro-2,4,6-trideoxyhexose produced were quantified by HPLC analysis. The ratio of the total amount of the produced 4-chloro-3-hydroxybutylaldehyde and 6-chloro-2,4,6-trideoxyhexose to the corresponding amount in the control was calculated.

Likewise, to a 100 mM acetic acid-sodium acetate buffer solution (pH 5.5) containing 100 mM of chloroacetaldehyde, 250 µg of *Pyrobaculum aerophilum*-derived DERA was added, and the solution was incubated at 25°C for 30 minutes. After the incubation, acetaldehyde was added to the solution at a concentration of 100 mM, and aldol condensation reaction was performed at 25°C for 2 hours. For the control, 250 µg of *Pyrobaculum aerophilum*-derived DERA was added to a 100 mM acetic acid-sodium acetate buffer solution (pH 5.5) containing 100 mM of chloroacetaldehyde, followed by the addition of acetaldehyde at a concentration of 100 mM, and aldol condensation reaction was performed at 25°C for 2 hours. The reaction was terminated by filtering the reaction solution through an ULTRAFREE-MC filter (manufactured by Millipore Corp.) to remove the proteins, and the amounts of 4-chloro-3-hydroxybutylaldehyde and 6-chloro-2,4,6-trideoxyhexose produced were quantified by HPLC analysis. The ratio of the total amount of the produced 4-chloro-3-

hydroxybutylaldehyde and 6-chloro-2,4,6-trideoxyhexose to the corresponding amount in the control was calculated.

Likewise, 250 µg of *E. coli*-derived DERA was added to a 100 mM Tris-HCl buffer solution (pH 7.5) containing 100 mM of
5 chloroacetaldehyde, and the solution was incubated at 25°C for 30 minutes. After the incubation, acetaldehyde was added to the solution at a concentration of 100 mM, and aldol condensation reaction was performed at 25°C for 2 hours. For the control, 250 µg of *Pyrobaculum aerophilum*-derived DERA was added to a 100
10 mM Tris-HCl buffer solution (pH 7.5) containing 100 mM of chloroacetaldehyde, followed by the addition of acetaldehyde to the solution at a concentration of 100 mM, and an aldol condensation reaction was performed at 25°C for 2 hours. The reaction was terminated by filtering the reaction solution
15 through an ULTRAFREE-MC filter (manufactured by Millipore Corp.) to remove the proteins, and the produced amounts of 4-chloro-3-hydroxybutylaldehyde and 6-chloro-2,4,6-trideoxyhexose were quantified by HPLC analysis. The ratio of the total amount of the produced 4-chloro-3-hydroxybutylaldehyde and 6-chloro-2,4,6-
20 trideoxyhexose to the corresponding amount in the control was calculated.

The results of evaluation for the resistance to chloroacetaldehyde of *Thermotoga maritima*-derived DERA, *Pyrobaculum aerophilum*-derived DERA and *E. coli*-derived DERA by
25 measuring the amount of 4-chloro-3-hydroxybutylaldehyde are presented in Table 2.

Method for quantification of 4-chloro-3-hydroxybutylaldehyde and 6-chloro-2,4,6-trideoxyhexose by high performance liquid chromatography (HPLC)

Analysis was performed by using a Develosil RPAQUEOUS column (manufactured by Nomura Chemical Co., Ltd.) as an HPLC column, at a column temperature of 40°C with water as the eluent. The applied amount was 20 µl, and the detection was performed by using a RI detector (manufactured by JASCO Corp.).

[Table 2]

Enzyme	Chloroacetaldehyde resistance value (%)
<i>Thermotoga maritima</i> -derived DERA	133
<i>Pyrobaculum aerophilum</i> -derived DERA	98
<i>E. coli</i> -derived DERA	15

EXAMPLE 5

Aldol condensation of chloroacetaldehyde and acetaldehyde by *Thermotoga maritima*-derived DERA

Aldol condensation reaction was performed at 25°C for 24 hours after the addition of 400 µg (0.23 U) of *Thermotoga maritima*-derived DERA to 1 ml of a reaction solution comprising 100 mM citric acid-sodium citrate buffer solution (pH 6.5), 300 mM acetaldehyde, and 100 mM chloroacetaldehyde. The reaction solution was filtered through an ULTRAFREE-MC filter

(manufactured by Millipore Corp.) to remove the proteins, and then the total amount of the produced 4-chloro-3-

hydroxybutylaldehyde and 6-chloro-2,4,6-trideoxyhexose was quantified by HPLC. The conversion rate of chloroacetaldehyde determined from the total amount of the products was 95%. The

conversion rate of chloroacetaldehyde determined from the amount

of 6-chloro-2,4,6-trideoxyhexose produced was 90%. The reaction solution was extracted with twice the volume of ethyl acetate three times, and the three fractions of ethyl acetate phase were combined and concentrated under reduced pressure. The

5 concentrate was dissolved in a small amount of ethyl acetate, and the solution was applied to silica gel column chromatography.

The solution was eluted with ethyl acetate/hexane(9:1) to fractionate 4-chloro-3-hydroxybutylaldehyde and 6-chloro-2,4,6-trideoxyhexose. The products separated by the column were

10 respectively analyzed by ^1H -NMR and ^{13}C -NMR, and it was confirmed that the products coincided with the reports in Patent Document 1 and Non-Patent Document 2.

EXAMPLE 6

15 Aldol condensation of chloroacetaldehyde and acetaldehyde by *Pyrobaculum aerophilum*-derived DERA

Aldol condensation reaction was performed at 25°C for 24 hours after the addition of 400 μg (0.04 U) of *Pyrobaculum aerophilum*-derived DERA to 1 ml of a reaction solution

20 comprising 100 mM acetic acid-sodium acetate buffer solution (pH 5.5), 300 mM acetaldehyde, and 100 mM chloroacetaldehyde. The reaction solution was filtered through an ULTRAFREE-MC filter (manufactured by Millipore Corp.) to remove the proteins, and then the total amount of 4-chloro-3-hydroxybutylaldehyde and 6-chloro-2-4,6-trideoxyhexose produced was quantified by HPLC.

25 The conversion rate of chloroacetaldehyde determined from the total amount the products was 93%. The conversion rate of

chloroacetaldehyde determined from the amount of 6-chloro-2,4,6-trideoxyhexose produced was 50%. The reaction solution was extracted with twice the volume of ethyl acetate three times, and the three fractions of ethyl acetate phase were combined and concentrated under reduced pressure. The concentrate was dissolved in a small amount of ethyl acetate, and the solution was applied to silica gel column chromatography. The solution was eluted with ethyl acetate/hexane (9:1), to fractionate 4-chloro-3-hydroxybutylaldehyde and 6-chloro-2,4,6-trideoxyhexose. The column separation products were respectively analyzed by ^1H -NMR and ^{13}C -NMR, and it was confirmed that the products coincided with the reports in Patent Document 1 and Non-Patent Document 2.

REFERENCE EXAMPLE 2

Aldol condensation of chloroacetaldehyde and acetaldehyde by *E. coli*-derived DERA

Aldol condensation reaction was performed at 25°C for 24 hours after the addition of 400 μg (24.4 U) of *E. coli*-derived DERA to 1 ml of a reaction solution comprising 100 mM Tris-HCl buffer solution (pH 7.5), 300 mM acetaldehyde (available from Junsei Chemical Co., Ltd.), and 100 mM chloroacetaldehyde (available from Tokyo Chemical Industry Co., Ltd.). The reaction solution was filtered through an ULTRAFREE-MC filter (manufactured by Millipore Corp.) to remove the proteins, and then the total amount of 4-chloro-3-hydroxybutylaldehyde and 6-chloro-2,4,6-trideoxyhexose produced was quantified by HPLC.

The conversion rate of chloroacetaldehyde determined from the total amount of the products was 4%.

EXAMPLE 7

5 Process for synthesizing 4-chloro-3-hydroxybutylaldehyde by
subjecting chloroacetaldehyde to aldol condensation with a
single molecule of acetaldehyde

Aldol condensation reaction was performed at 25°C for 24
hours after the addition of 400 µg (0.04 U) of *Pyrobaculum*
10 *aerophilum*-derived DERA to 1 ml of a reaction solution
comprising 100 mM acetic acid-sodium acetate buffer solution (pH
5.5), 100 mM acetaldehyde, and 100 mM chloroacetaldehyde. The
reaction solution was filtered through an ULTRAFREE-MC filter
(manufactured by Millipore Corp.) to remove the proteins, and
15 the total amount of 4-chloro-3-hydroxybutylaldehyde and 6-
chloro-2,4,6-trideoxyhexose produced was quantified by HPLC.
The conversion rate of chloroacetaldehyde determined from the
total amount of the products was 90%. The conversion rate of
chloroacetaldehyde determined from the amount of 4-chloro-3-
20 hydroxybutylaldehyde produced was 80%. The reaction solution
was extracted with twice the volume of ethyl acetate three times,
the ethyl acetate layers were combined, and ethyl acetate was
evaporated under reduced pressure. The obtained oily product
was dissolved in a small amount of ethyl acetate, and subjected
25 to silica gel chromatography with ethyl acetate/n-hexane (9:1)
as the eluent to isolate 4-chloro-3-hydroxybutylaldehyde. The
isolated 4-chloro-3-hydroxybutylaldehyde was analyzed by ¹H-NMR

and ^{13}C -NMR, and it was confirmed that the product coincided with the report in Non-Patent Document 2, and was confirmed to be 4-chloro-3-hydroxybutylaldehyde. Furthermore, the optical purity measured by HPLC analysis was verified to be 97.8%ee.

5 Analysis of optical purity by HPLC

The reaction solution was cooled to 4°C and was adjusted to pH 9.0 with 10% sodium hydroxide aqueous solution. Then, sodium borohydride was added, and the mixture was stirred for 30 minutes. The reaction solution was adjusted to pH 6.0 with 2 N
10 hydrochloric acid in order to decompose the remaining sodium borohydride. Then, the reaction solution was extracted with twice the volume of ethyl acetate three times, the ethyl acetate layers were combined, and ethyl acetate was evaporated under reduced pressure. The obtained oily product was dissolved
15 in a small amount of n-hexane/ethanol (50:50), and analyzed by HPLC. Analysis was performed by using a CHIRALPAK AD-H column (manufactured by Daicel Chemical Industries, Ltd.) as the HPLC column, at a column temperature of 40°C, with n-hexane/ethanol (92.5:7.5) as the eluent. The amount applied was 10 μl , and the
20 detection was performed by using a RI detector (manufactured by JASCO Corp.).

EXAMPLE 8

Aldol condensation of various aliphatic aldehydes and
25 acetaldehyde by *Thermotoga maritima*-derived DERA

Aldol condensation reaction was performed at 25°C after the addition of 400 μg (0.23 U) of *Thermotoga maritima*-derived DERA

to 1 ml of a reaction solution comprising 100 mM citric acid-
sodium citrate buffer solution (pH 6.5), 100 mM acetaldehyde,
and 100 mM each of various aliphatic aldehydes (propionaldehyde,
butylaldehyde, n-valeraldehyde, isobutylaldehyde, adipate
5 semialdehyde methyl ester, and succinate semialdehyde).

The reaction solution was filtered through an ULTRAFREE-MC
filter (manufactured by Millipore Corp.) to remove the proteins,
and then the compounds produced by aldol condensation reaction
of various aliphatic aldehydes and acetaldehyde were detected by
10 means of the spots formed by thin layer chromatography (TLC)
analysis. For all of the aliphatic aldehydes used as substrates
in the reaction, the corresponding products of aldol
condensation with acetaldehyde were detected.

TLC analysis conditions

15 Silica gel plate: Silica Gel 60 (manufactured by Merck &
Co., Inc.)

Developing solution: Ethyl acetate: n-hexane = 9:1

Spotted amount: 1 μ l of reaction solution

Detecting method: 12-molybdo(VI)phosphoric acid n-hydrate
20 (available from Wako Pure Chemical Industries, Ltd.) was
dissolved in ethanol to make 7% solution, and a silica gel plate
having samples applied thereon was immersed in the solution and
heated for color development.

25 EXAMPLE 9

Aldol condensation of various aliphatic aldehydes with
acetaldehyde by *Pyrobaculum aerophilum*-derived DERA

Aldol condensation reaction was performed at 25°C after the addition of 400 µg (0.04 U) of *Pyrobaculum aerophilum*-derived DERA to 1 ml of a reaction solution comprising 100 mM acetic acid-sodium acetate buffer solution (pH 5.5), 100 mM
5 acetaldehyde, and 100 mM each of various aliphatic aldehydes (propionaldehyde, butylaldehyde, n-valeraldehyde, isobutylaldehyde, adipate semialdehyde methyl ester, and succinate semialdehyde).

The reaction solution was filtered through an ULTRAFREE-MC
10 filter (manufactured by Millipore Corp.) to remove the proteins, and then the aldol condensation reaction compounds formed from various aliphatic aldehydes and acetaldehyde were detected by means of the spots formed by thin layer chromatography (TLC) analysis.

15 For all of the aliphatic aldehydes used as substrates in the reaction, the corresponding products of aldol condensation with acetaldehyde were detected.

TLC analysis conditions

Silica gel plate: Silica Gel 60 (manufactured by Merck &
20 Co., Inc.)

Developing solution: Ethyl acetate: n-hexane = 9:1

Spotted amount: 1 µl of reaction solution

Detecting method: 12-molybdo(VI)phosphoric acid n-hydrate (available from Wako Pure Chemical Industries, Ltd.) was
25 dissolved in ethanol to make 7% solution, and a silica gel plate having samples applied thereon was immersed in the solution and heated for color development.

Industrial Applicability

DERA derived from hyperthermophilic bacteria and the like,
which is used in the producing process of the present invention,
5 has high catalytic activity for the aldol condensation reaction
using non-natural substrates, and has high enzyme stability even
at high substrate concentrations. Thus, the producing process
of the invention can enhance the productivity of chiral
hydroxyaldehyde compounds per reactor, compared with
10 conventional processes using *E. coli*-derived DERA.

CLAIMS

1. A process for producing a hydroxyaldehyde compound,
comprising conducting aldol condensation of a substituted or
5 unsubstituted aliphatic aldehyde compound having 2 to 6 carbon
atoms with a single molecule of acetaldehyde to produce a
hydroxyaldehyde compound having the number of carbon atoms
increased by two, using D-2-deoxyribose-5-phosphate aldolase
having a property of retaining 50 % or greater of activity after
10 treating at 25°C for 30 minutes in an aqueous medium containing
100 mM of chloroacetaldehyde.






2. The process according to claim 1, wherein the D-2-
deoxyribose-5-phosphate aldolase has a feature of either (1) or
15 (2) in the following:


(1) Having an amino acid sequence of SEQ ID NO: ~~1-2~~ or SEQ
ID NO. ~~24~~; and

(2) Having an amino acid sequence of SEQ ID NO: ~~1-2~~ or SEQ
ID NO: ~~24~~, in which one to several amino acids are deleted or
20 substituted by other amino acid residues, or other amino acid
residues are inserted.

3. The process according to claim 2, wherein the substituted
or unsubstituted aliphatic aldehyde compound having 2 to 6
25 carbon atoms is a compound represented by General Formula (1),
General Formula (2) or General Formula (3), and the
corresponding aldehyde compound having the number of carbon

atoms increased by two, which is obtained by aldol condensation, is an aldehyde compound represented by General Formula (4), General Formula (5) or General Formula (6), respectively:





wherein in General Formula (1) to General Formula (6), R_1 is a hydrogen atom, a hydroxyl group, a halogen atom, an azido group, a carboxyl group, or an alkyl group, an alkoxy group or an alkanolic acid group respectively having 1 to 4 carbon atoms; R_2 is a hydrogen atom, a hydroxyl group or a methyl group; and R_3 is a hydrogen atom or a hydroxyl group.

4. The process according to claim 3, wherein acetaldehyde is used in an amount ranging from 0.5 molar equivalents to 3.0 molar equivalents based on an amount of the compound represented by General Formula (1), General Formula (2) or General Formula (3).

5. The process according to claim 4, wherein D-2-deoxyribose-5-phosphate aldolase is used at a ratio of 0.1 U/mmol to 80 U/mmol (1 U represents the amount of enzyme which decomposes 1 μ mol of D-2-deoxyribose-5-phosphate into D-glyceraldehyde-3-phosphate and acetaldehyde at 25°C in 1 minute), relative to the total number of moles of the aldehyde compound represented by General Formula (1), General Formula (2) or General Formula (3), and acetaldehyde.

6. The process according to claim 5, wherein the aldehyde compound represented by General Formula (1), General Formula (2) or General Formula (3) is an aldehyde selected from acetaldehyde, chloroacetaldehyde, glycolaldehyde, propionaldehyde, butylaldehyde, isobutylaldehyde, 3,4-dihydroxybutylaldehyde, malonate semialdehyde, succinate semialdehyde and adipate semialdehyde.

7. A process for producing a hydroxyaldehyde compound, comprising conducting aldol condensation of a substituted or unsubstituted aliphatic aldehyde compound having 2 to 6 carbon atoms with two molecules of acetaldehyde to produce a hydroxyaldehyde compound having the number of carbon atoms increased by four, using D-2-deoxyribose-5-phosphate aldolase (or cells containing the enzyme or a lysate thereof) having a property of retaining 50 % or greater of activity after treating at 25°C for 30 minutes in an aqueous medium containing 100 mM of chloroacetaldehyde.



8. The process according to claim 7, wherein the D-2-deoxyribose-5-phosphate aldolase has a feature of either (1) or (2) in the following:

(1) Having an amino acid sequence of SEQ ID NO: 1-2 or SEQ ID NO: 24; and

(2) Having an amino acid sequence of SEQ ID NO: 1-2 or SEQ ID NO: 24, in which one to several amino acids are deleted or

substituted by other amino acid residues, or other amino acid residues are inserted.

9. The process according to claim 8, wherein the substituted
5 or unsubstituted aliphatic aldehyde compound having 2 to 6 carbon atoms is a compound represented by General Formula (1), and the hydroxylaldehyde compound having the number of carbon atoms increased by four is a compound represented by General Formula (7):



wherein in General Formula (7), R₁ is a hydrogen atom, a hydroxyl group, a halogen atom, an azido group, a carboxyl group, or an alkoxy group having 1 to 4 carbon atoms.

15

10. The process according to claim 9, wherein D-2-deoxyribose-5-phosphate aldolase is used for the reaction at a ratio of 0.1 U/mmol to 120 U/mmol (1 U represents the amount of enzyme which decomposes 1 μmol of D-2-deoxyribose-5-phosphate into D-
20 glyceraldehyde-3-phosphate and acetaldehyde at 25°C in 1 minute), relative to the total number of moles of the compound represented by General Formula (1) and acetaldehyde (in General

Formula (7), R_1 is a hydrogen atom, a hydroxyl group, a halogen atom, an azido group, a carboxyl group, or an alkoxy group having 1 to 4 carbon atoms).

- 5 11. The process according to claim 10, wherein the compound represented by General Formula (1) is an aldehyde selected from acetaldehyde, chloroacetaldehyde, glycolaldehyde, propionaldehyde, butylaldehyde, 3,4-dihydroxybutylaldehyde, malonate semialdehyde, succinate semialdehyde, and adipate
10 semialdehyde.

ABSTRACT

An industrial process for producing hydroxyaldehydes efficiently, by solving the problems of conventional DERA, such as low stability against aldehydes, low catalytic activity for aldol condensation, and the difficulty of controlling the number of acetaldehyde molecules to be condensed, is provided.

According to the process, aldol condensation of a substituted or unsubstituted aliphatic aldehyde compound having 2 to 6 carbon atoms with acetaldehyde is conducted by using D-2-deoxyribose-5-phosphate aldolase which is highly stable against aldehydes and has high catalytic activity for aldol condensation, whereby a hydroxyaldehyde compound having the number of carbon atoms increased by two or four can be produced.

Fig.1

